August 25, 2016 9:29 PM ET


Company Overview of Merck Research Laboratories

Company Overview

Merck Research Laboratories discovers and develops medicines for cancer and neurodegenerative disorders. The company was founded in 2004 and is based in Boston, Massachusetts. Merck Research Laboratories operates as a subsidiary of Merck & Co. Inc.

33 Avenue Louis Pasteur

Boston, MA 02115

United States

Founded in 2004



Key Executives for Merck Research Laboratories

Senior Vice President and Franchise Head of Immunology, Respiratory, and Endocrine
Age: 62
Senior Vice President and Franchise Head of Diabetes and Obesity
Senior Vice President and Head of Neuroscience and Ophthalmology
Age: 60
Director of Human Resources
Compensation as of Fiscal Year 2016.

Merck Research Laboratories Key Developments

Merck Research Laboratories Presents at 13th Annual BIO Asia International Conference 2016, Mar-16-2016 03:45 PM

Merck Research Laboratories Presents at 13th Annual BIO Asia International Conference 2016, Mar-16-2016 03:45 PM. Venue: Grand Hyatt, Tokyo, Japan. Speakers: Ji Li, Vice President, Business Development & Licensing.

ImmunoGen Enters into Clinical Research Collaboration with Merck

ImmunoGen, Inc. and Merck have entered into a clinical research collaboration for the assessment of ImmunoGen's mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, Keytruda, or pembrolizumab, for the treatment of patients with FR¦Á-positive ovarian cancer. ImmunoGen is conducting a Phase Ib/II clinical trial, FORWARD II, that evaluates mirvetuximab soravtansine for FR¦Á-positive ovarian cancer used in doublet combination with other anticancer agents. The assessment of mirvetuximab soravtansine with Keytruda will be added to this trial, with Merck supplying the Keytruda. ImmunoGen expects this cohort to open for patient enrollment in the second half of 2016. The agreement is between ImmunoGen and Merck, through a subsidiary. The agreement includes a provision for potential expansion of the collaboration to include a subsequent Phase III clinical trial. ImmunoGen developed mirvetuximab soravtansine as a potential treatment for ovarian cancer and other FR¦Á-positive solid tumors. In early clinical testing, mirvetuximab soravtansine demonstrated notable activity when used as a single agent to treat platinum-resistant FR¦Á-positive ovarian cancer. ImmunoGen is assessing the ADC used as a single agent for pretreated FR¦Á-positive ovarian cancer in its Phase II trial, FORWARD I, which is intended to support an Accelerated Approval pathway. Mirvetuximab soravtansine is also now being assessed in separate combinations with pegylated liposomal doxorubicin (Doxil), bevacizumab (Avastin), and carboplatin in the Phase Ib/II trial, FORWARD II.

Merck Research Laboratories Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2016 08:30 AM

Merck Research Laboratories Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2016 08:30 AM. Venue: 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Iain Dukes, SVP, Business Development & Licensing.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Merck Research Laboratories, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at